JP2017526744A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526744A5 JP2017526744A5 JP2017528765A JP2017528765A JP2017526744A5 JP 2017526744 A5 JP2017526744 A5 JP 2017526744A5 JP 2017528765 A JP2017528765 A JP 2017528765A JP 2017528765 A JP2017528765 A JP 2017528765A JP 2017526744 A5 JP2017526744 A5 JP 2017526744A5
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- peg
- antifolate
- poly
- dspe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 41
- 239000002502 liposome Substances 0.000 claims 36
- 239000004052 folic acid antagonist Substances 0.000 claims 33
- 230000003432 anti-folate effect Effects 0.000 claims 27
- 229940127074 antifolate Drugs 0.000 claims 27
- 229920001223 polyethylene glycol Polymers 0.000 claims 23
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 14
- 239000002202 Polyethylene glycol Substances 0.000 claims 12
- 230000000975 bioactive effect Effects 0.000 claims 12
- 239000007864 aqueous solution Substances 0.000 claims 11
- 239000003381 stabilizer Substances 0.000 claims 11
- 239000003937 drug carrier Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 7
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 7
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 7
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 claims 7
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 claims 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 7
- 235000012000 cholesterol Nutrition 0.000 claims 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 6
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 6
- 229920002401 polyacrylamide Polymers 0.000 claims 6
- -1 DSPE-PEG-maleimide Chemical compound 0.000 claims 4
- 239000012867 bioactive agent Substances 0.000 claims 4
- 102000006815 folate receptor Human genes 0.000 claims 4
- 108020005243 folate receptor Proteins 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 3
- 150000008575 L-amino acids Chemical class 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 229920006187 aquazol Polymers 0.000 claims 3
- 239000012861 aquazol Substances 0.000 claims 3
- 229920005601 base polymer Polymers 0.000 claims 3
- 229960001438 immunostimulant agent Drugs 0.000 claims 3
- 239000003022 immunostimulating agent Substances 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 229920000773 poly(2-methyl-2-oxazoline) polymer Polymers 0.000 claims 3
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims 3
- 229920002187 poly[N-2-(hydroxypropyl) methacrylamide] polymer Polymers 0.000 claims 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
- 239000000600 sorbitol Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims 2
- 229920002498 Beta-glucan Polymers 0.000 claims 2
- 102000010451 Folate receptor alpha Human genes 0.000 claims 2
- 108050001931 Folate receptor alpha Proteins 0.000 claims 2
- 102000010449 Folate receptor beta Human genes 0.000 claims 2
- 108050001930 Folate receptor beta Proteins 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 2
- 102100023119 Sperm-egg fusion protein Juno Human genes 0.000 claims 2
- 101710093389 Sperm-egg fusion protein Juno Proteins 0.000 claims 2
- 229960003896 aminopterin Drugs 0.000 claims 2
- 239000008365 aqueous carrier Substances 0.000 claims 2
- 239000003125 aqueous solvent Substances 0.000 claims 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims 2
- 239000001639 calcium acetate Substances 0.000 claims 2
- 229960005147 calcium acetate Drugs 0.000 claims 2
- 235000011092 calcium acetate Nutrition 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical group N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 claims 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical group C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 claims 2
- 239000003944 phosphoribosylglycinamide formyltransferase inhibitor Substances 0.000 claims 2
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 claims 2
- 229960000214 pralatrexate Drugs 0.000 claims 2
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 claims 2
- 229960005385 proguanil Drugs 0.000 claims 2
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims 2
- 229960000611 pyrimethamine Drugs 0.000 claims 2
- 150000004944 pyrrolopyrimidines Chemical class 0.000 claims 2
- 239000001632 sodium acetate Substances 0.000 claims 2
- 235000017281 sodium acetate Nutrition 0.000 claims 2
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 claims 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 229920001503 Glucan Polymers 0.000 claims 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229950000909 lometrexol Drugs 0.000 claims 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000004882 non-tumor cell Anatomy 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 1
- 229960001082 trimethoprim Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037597P | 2014-08-14 | 2014-08-14 | |
| US62/037,597 | 2014-08-14 | ||
| US201562130493P | 2015-03-09 | 2015-03-09 | |
| US62/130,493 | 2015-03-09 | ||
| US201562133265P | 2015-03-13 | 2015-03-13 | |
| US62/133,265 | 2015-03-13 | ||
| PCT/US2015/045353 WO2016025882A2 (en) | 2014-08-14 | 2015-08-14 | Liposome encapsulated affinity drug |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526744A JP2017526744A (ja) | 2017-09-14 |
| JP2017526744A5 true JP2017526744A5 (enExample) | 2018-09-20 |
| JP6825764B2 JP6825764B2 (ja) | 2021-02-03 |
Family
ID=55304769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528765A Active JP6825764B2 (ja) | 2014-08-14 | 2015-08-14 | リポソームカプセル化親和性薬物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20160228573A1 (enExample) |
| EP (1) | EP3188724B1 (enExample) |
| JP (1) | JP6825764B2 (enExample) |
| KR (1) | KR102505508B1 (enExample) |
| CN (2) | CN106794164A (enExample) |
| AP (1) | AP2017009766A0 (enExample) |
| AU (4) | AU2015301462B2 (enExample) |
| BR (1) | BR112017002767B1 (enExample) |
| CA (1) | CA2957775C (enExample) |
| DK (1) | DK3188724T3 (enExample) |
| EA (1) | EA201790378A1 (enExample) |
| ES (1) | ES2905498T3 (enExample) |
| MA (1) | MA40428A (enExample) |
| MX (1) | MX386433B (enExample) |
| WO (1) | WO2016025882A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2833918B1 (en) | 2012-04-05 | 2019-05-08 | Massachusetts Institute of Technology | Immunostimulatory compositions and methods of use thereof |
| CN108289845A (zh) | 2015-09-14 | 2018-07-17 | 维吉思康科技公司 | 皮下、舌下和口服治疗用空间稳定载体、用于治疗哺乳动物的组合物和方法 |
| US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| CN120939250A (zh) * | 2016-08-12 | 2025-11-14 | L.E.A.F.控股集团公司 | 聚谷氨酸化抗叶酸剂及其用途 |
| WO2018031967A1 (en) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| WO2018031980A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| CN106750252B (zh) * | 2016-12-05 | 2018-11-30 | 山东大学齐鲁医院 | 二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000-双叶酸及其制备方法和应用 |
| CN110891549A (zh) * | 2017-04-07 | 2020-03-17 | 玛亚实验室公司 | 改善治疗剂的溶解度和生物利用度的方法 |
| US11583578B2 (en) | 2017-04-28 | 2023-02-21 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Plasmodium falciparum recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery |
| JP7491573B2 (ja) * | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| WO2019157133A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| WO2019157123A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| US12239734B2 (en) | 2018-02-07 | 2025-03-04 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| WO2019157138A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pemetrexed and uses thereof |
| EP3749313A4 (en) * | 2018-02-07 | 2022-03-16 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATE ANTIFOLATES AND ASSOCIATED USES |
| JP7490240B2 (ja) * | 2018-02-07 | 2024-05-27 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用 |
| CA3090506A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated tetrahydrofolates and uses thereof |
| CN111954530A (zh) * | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | γ聚谷氨酸化培美曲塞及其用途 |
| US11730738B2 (en) | 2018-02-07 | 2023-08-22 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| US12246019B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| EP3752156A4 (en) * | 2018-02-14 | 2021-10-27 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF |
| CN111936145A (zh) * | 2018-02-14 | 2020-11-13 | L.E.A.F.控股集团公司 | γ聚谷氨酸化氨甲蝶呤及其用途 |
| EP3755335A4 (en) * | 2018-02-14 | 2022-06-22 | L.E.A.F Holdings Group LLC | GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES |
| CA3090875A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| GB201814959D0 (en) * | 2018-09-14 | 2018-10-31 | Secr Defence | Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses |
| JP2022525781A (ja) | 2019-03-20 | 2022-05-19 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫細胞療法における両親媒性物質の使用およびそのための組成物 |
| CN118203546A (zh) * | 2019-05-07 | 2024-06-18 | 米尼翁大学 | 生产脂质体的方法 |
| WO2020257260A1 (en) | 2019-06-17 | 2020-12-24 | Massachusetts Institute Of Technology | Formulation of peptide loaded liposomes and related applications |
| WO2021150770A1 (en) * | 2020-01-21 | 2021-07-29 | University Of Virginia Patent Foundation | Oncogenic trim37 is a targetable epigenetic driver of metastasis and links chemoresistance and metastatic fate in triple-negative breast cancer |
| WO2022081838A1 (en) * | 2020-10-14 | 2022-04-21 | Georgia Tech Research Corporation | Synthetic antigens as chimeric antigen receptor (car) ligands and uses thereof |
| WO2022235907A1 (en) | 2021-05-05 | 2022-11-10 | Vgsk Technologies, Inc. | Liposome-encapsulated corticosteriods inhibit sars-cov-2 replication and reduces lung inflammation |
| WO2025005632A1 (ko) * | 2023-06-26 | 2025-01-02 | 주식회사 무진메디 | 이온화 가능한 펩타이드를 이용한 지질 나노입자 기반 약물 전달체 및 이의 제조방법 |
| KR102898792B1 (ko) * | 2023-06-26 | 2025-12-19 | 주식회사 무진메디 | 이온화 가능한 펩타이드를 이용한 지질 나노입자 기반 약물 전달체 및 이의 제조방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| CN100346784C (zh) * | 2002-02-22 | 2007-11-07 | 先灵公司 | 抗肿瘤剂,特别是替莫唑胺的药物制剂,其制备方法和用途 |
| US20100210745A1 (en) * | 2002-09-09 | 2010-08-19 | Reactive Surfaces, Ltd. | Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes |
| US8241663B2 (en) * | 2004-03-26 | 2012-08-14 | Terumo Kabushiki Kaisha | Liposome preparation |
| US20110022529A1 (en) * | 2009-07-22 | 2011-01-27 | Fernando Barsoba | Social network creation using image recognition |
| US8747869B2 (en) * | 2010-03-19 | 2014-06-10 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
| WO2011150392A1 (en) * | 2010-05-28 | 2011-12-01 | Purdue Research Foundation | Delivery of therapeutic agents to inflamed tissues using folate-targeted agents |
| WO2012031205A2 (en) * | 2010-09-03 | 2012-03-08 | The Brigham And Women's Hospital, Inc. | Lipid-polymer hybrid particles |
| EP3401333B1 (en) * | 2010-09-09 | 2021-05-19 | Purdue Research Foundation | Anti-human folate receptor beta antibodies and methods of use |
| JP6049712B2 (ja) * | 2011-07-08 | 2016-12-21 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ | 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子 |
| SMT202000485T1 (it) * | 2011-07-13 | 2020-11-10 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Liposomi co-incapsulanti un bisfosfonato e un agente anfipatico |
| US20130122096A1 (en) * | 2011-11-14 | 2013-05-16 | Silenseed Ltd. | Compositions for drug delivery and methods of manufacturing and using same |
| WO2013084208A2 (pt) * | 2011-12-07 | 2013-06-13 | Universidade Do Minho | Lipossomas e respetivo método de produção |
| US20140120157A1 (en) * | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
-
2015
- 2015-08-14 AU AU2015301462A patent/AU2015301462B2/en active Active
- 2015-08-14 EP EP15832081.2A patent/EP3188724B1/en active Active
- 2015-08-14 BR BR112017002767-4A patent/BR112017002767B1/pt active IP Right Grant
- 2015-08-14 CN CN201580054566.5A patent/CN106794164A/zh active Pending
- 2015-08-14 MA MA040428A patent/MA40428A/fr unknown
- 2015-08-14 CN CN202310777450.0A patent/CN117159470A/zh active Pending
- 2015-08-14 US US14/826,967 patent/US20160228573A1/en not_active Abandoned
- 2015-08-14 DK DK15832081.2T patent/DK3188724T3/da active
- 2015-08-14 MX MX2017001881A patent/MX386433B/es unknown
- 2015-08-14 JP JP2017528765A patent/JP6825764B2/ja active Active
- 2015-08-14 WO PCT/US2015/045353 patent/WO2016025882A2/en not_active Ceased
- 2015-08-14 ES ES15832081T patent/ES2905498T3/es active Active
- 2015-08-14 CA CA2957775A patent/CA2957775C/en active Active
- 2015-08-14 KR KR1020177006638A patent/KR102505508B1/ko active Active
- 2015-08-14 EA EA201790378A patent/EA201790378A1/ru unknown
- 2015-08-14 AP AP2017009766A patent/AP2017009766A0/en unknown
-
2020
- 2020-05-19 AU AU2020203241A patent/AU2020203241A1/en not_active Abandoned
-
2022
- 2022-03-24 AU AU2022202046A patent/AU2022202046A1/en not_active Abandoned
-
2024
- 2024-06-05 US US18/734,619 patent/US20250066468A1/en active Pending
- 2024-08-02 AU AU2024205501A patent/AU2024205501A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526744A5 (enExample) | ||
| JP2019524885A5 (enExample) | ||
| JP2019524802A5 (enExample) | ||
| KR102584446B1 (ko) | 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도 | |
| JP2025072362A5 (enExample) | ||
| O Elzoghby et al. | Natural polymeric nanoparticles for brain-targeting: implications on drug and gene delivery | |
| Urban et al. | Nanotools for the delivery of antimicrobial peptides | |
| US20170232115A1 (en) | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof | |
| KR20160110410A (ko) | 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도 | |
| JPWO2019157138A5 (enExample) | ||
| JP2016513090A5 (enExample) | ||
| JPWO2019157145A5 (enExample) | ||
| JPWO2019160735A5 (enExample) | ||
| JPWO2019157146A5 (enExample) | ||
| JPWO2019157148A5 (enExample) | ||
| JPWO2019157120A5 (enExample) | ||
| US20210393799A1 (en) | Dendritic polymers complexed with immune checkpoint inhibitors for enhanced cancer immunotherapy | |
| Zhang et al. | Advances in long-circulating drug delivery strategy | |
| JPWO2019157125A5 (enExample) | ||
| Talevi et al. | Applications of nanosystems to anticancer drug therapy (Part I. Nanogels, nanospheres, nanocapsules) | |
| Shi et al. | Advances in nanotherapy for targeting senescent cells | |
| US20230270882A1 (en) | Peptide-nanoparticle conjugates | |
| CN111107842A (zh) | 利用微混合和卡培他滨两亲性特性的卡培他滨的聚合物-脂质混杂纳米颗粒 | |
| KR20220092557A (ko) | 펩티드-나노입자 접합체 | |
| TWI472341B (zh) | 寡聚物奈米顆粒複合體釋放系統 |